Skip to content

NIH launches research network to evaluate emerging cancer screening technologies

The National Institutes of Health (NIH) has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshot? by investigating how to identify cancers earlier, when they may be easier to treat. Eight groups have received funding from the National Cancer Institute (NCI), part of NIH, to carry out the initial activities of the network. In 2024, the network will launch a pilot study, known as the Vanguard Study on Multi-Cancer Detection, to address the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials. MCDs are blood tests that can screen for several types of cancers. The study will enroll up to 24,000 people to inform the design of a much larger randomized controlled trial. This larger trial will evaluate whether the benefits… 

more »NIH launches research network to evaluate emerging cancer screening technologies

Bavarian Nordic delivered record financial results in 2023

COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities. The post Bavarian Nordic delivered record financial results in 2023 appeared first on Bio Tech Winners. Bavarian Nordic delivered record financial results in 2023

Researchers test "wonder material" on humans for the first time

Will it soon be possible to inhale medicine easily? Researchers have now successfully tested a potentially revolutionary nanomaterial on humans for the first time. They describe it as a "wonder material." Tests with face masks The scientists led by Dr. Mark Miller from the Center for Cardiovascular Science at the University of Edinburgh used for this first study, published in the journal Nature, [...] Researchers test "wonder material" safely on humans for the first time

IQWiG study: AMNOG takes effect with a time delay

For orphan drugs, the political goal of aligning the price with the additional benefit is only achieved through the subsequent regular benefit assessment. This is shown by a current IQWiG analysis. To promote the development of drugs for rare diseases (orphan drugs) despite economic risks, they are treated preferentially in Germany: New orphan drugs only have to demonstrate an additional benefit compared to the appropriate comparator therapy if they exceed the annual sales limit of 30 million euros (up to November 2022: 50 million euros). Previously, their additional benefit is considered proven, and the Gemeinsame Bundesausschuss (G-BA) merely quantifies the extent of the additional benefit based on the (marketing authorization) documents. If, within the scope of this "limited assessment," no classification into the categories "minor," "considerable," or "substantial" is possible, the G-BA must still attest a "non-quantifiable" additional benefit to the active ingredient. The Institute for Quality and Efficiency in Health Care (IQWiG) has now analyzed the impact of this preferential treatment of orphan drugs on the prices of...

more »IQWiG study: AMNOG takes effect with a time delay
man holding laptop computer with both hands

Berliner Hochschule für Technik  wurde gehackt

Ironie des Schicksals: In Sachen Cyberabwehr outet sich die Berliner Hochschule für Technik als komplett überfordert. Wir verzichten auf weitere Kommentare und geben die Mitteilung im Originalwortlaut weiter:

NRW: Digitales Analytiklabor geht an den Start

Das FutureLab.NRW am Institut für Umwelt und Energie, Technik und Analytik, einem An-Institut der Universität Duisburg-Essen ist offiziell eröffnet worden. Damit stärkt das Mitglied der Johannes-Rau-Forschungsgemeinschaft seine Expertise im Bereich Chemische Analytik, Automation und Digitalisierung.